Key Points
The insider liquidated 7,500 shares at a weighted average price of $82.02.
The disposition represented 2% of the executive's total reported equity holdings.
Following the transaction, the CEO maintains direct ownership of 377,820 shares and indirect ownership of 4,166 shares held through two family trusts.
Robert I. Blum, president & CEO of Cytokinetics, Incorporated (NASDAQ:CYTK), reported a sale of 7,500 shares of common stock on July 13, 2026, according to an SEC Form 4 filing.
Transaction summary
| Metric | Value |
|---|---|
| Transaction value | $615,150 |
| Shares sold | 7,500 |
| Post-transaction shares (directly held) | 377,820 |
| Post-transaction shares (indirectly held) | 4,166 |
| Post-transaction value | $31.41 million |
Transaction value based on SEC Form 4 weighted average sale price ($82.02); post-transaction value based on July 13, 2026 market close ($82.24).
Key questions
- What were the mechanics of this transaction?
The transaction involved the exercise of 7,500 stock options at a strike price of $10.60 per share, with the resulting equity immediately sold at a weighted average price of $82.02. - Who manages the indirect equity holdings reported in this filing?
The 4,166 shares held indirectly are divided between the Bridget Blum 2003 Irrevocable Trust and the Brittany Blum 2003 Irrevocable Trust, which both hold 2,083 shares. - What is the scale of the insider's remaining exposure?
In addition to the 381,986 shares of common stock held across direct and indirect accounts, the CEO continues to hold 186,745 derivative securities.
Company Overview
| Metric | Value |
|---|---|
| Share Price (as of market close 2026-07-13) | $82.24 |
| Market Capitalization | $10.2 billion |
| Revenue (TTM) | $105.8 million |
| Net Income (TTM) | -$829.6 million |
Company Snapshot
- Cytokinetics is a biopharmaceutical company that discovers, develops, and commercializes novel muscle activators and muscle inhibitors for the treatment of debilitating diseases, with MYQORZO, a cardiac myosin inhibitor for symptomatic obstructive hypertrophic cardiomyopathy, serving as its primary marketed product.
- The company generates revenue through the commercialization of its proprietary therapeutic compounds, including MYQORZO and pipeline candidates such as Aficamten and omecamtiv mecarbil, which target cardiac and skeletal muscle disorders.
- Cytokinetics' primary customers are healthcare providers and patients with rare genetic and acquired cardiac conditions, with a strategic focus on the treatment of hypertrophic cardiomyopathy and related muscle-mediated diseases in the United States and international markets.
Cytokinetics operates as a clinical-stage to commercial-stage biopharmaceutical enterprise with a market capitalization of roughly $10 billion, leveraging its proprietary muscle biology platform to develop targeted therapeutics for unmet medical needs in cardiac and skeletal muscle disorders. The company has achieved significant clinical validation with MYQORZO's market approval and maintains a robust pipeline of investigational compounds, positioning it as a specialized player in the rare disease and cardiology therapeutic space.
What this transaction means for investors
This sale ultimately looks like a CEO cashing in some deep-in-the-money options right as his company's first drug launch takes off, which isn’t a signal to worry about. Blum still holds nearly 382,000 shares across direct and indirect accounts, plus 186,745 options, so the overwhelming majority of his exposure is untouched. With the stock up 110% over the past year, a CEO converting cheap options on a fraction of his stake is just diversification, plain and simple.
The reason he's holding the rest is probably the launch itself and a lot of traction since. Cytokinetics booked its first U.S. product revenue in the first quarter, $4.8 million from MYQORZO in roughly nine weeks, with more than 275 doctors prescribing it to about 680 patients. The pivotal ACACIA-HCM trial also hit both primary goals, opening a path to expand the drug's use, and about $1.1 billion in cash funds the rollout. Blum called the launch a significant opportunity ahead. The firm has since launched the drug in Germany, as of last month, and gross proceeds of $805 million from an offering of common stock. Second-quarter earnings should provide clarity into how things have fared.
Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Cytokinetics. The Motley Fool has a disclosure policy.